Source comparison
Interpreting the comparison honestly
A common marketing claim is that these peptides are interchangeable “GH boosters.” The evidence does not support treating them as equivalent. Tesamorelin is the only compound in this group with two large replicated Phase 3 trials and an FDA-approved indication
This comparison does not assign a generated winner or score.
- A common marketing claim is that these peptides are interchangeable “GH boosters.” The evidence does not support treating them as equivalent. Tesamorelin is the only compound in this group with two large replicated Phase 3 trials and an FDA-approved indication built on hard imaging endpoints (CT-measured visceral fat). Sermorelin has a long historical safety record but its clinical data concentrate on pediatric GH deficiency. CJC-1295 and ipamorelin are supported mainly by pharmacology and small studies, not by large registrational trials, and their long-term human safety is not characterized to the same standard. When evidence strength — not just mechanism — is the yardstick, tesamorelin stands apart.